Catalyst

Slingshot members are tracking this event:

Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EXAS

100%

Additional Information

Additional Relevant Details Exact Sciences generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.

Cologuard's patient compliance rate was 68 percent as of June 30, 2016. The compliance rate is derived from the number of valid tests reported divided by the number of collection kits shipped to patients during the 12-month period ending 60 days prior to June 30, 2016. Cologuard's compliance rate may vary from quarter to quarter, reflecting, among other factors, changes in the mix of the insurance coverage of patients completing the test.
http://investor.exac...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 26, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cologuard, Patient Compliance Rate, Revenue